Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Good morning. We’ve made it to the end of what’s felt like an extremely long week. Wishing you all a restful weekend and lots of Super Bowl dips.
Roivant’s immune drug helped treat rare skin disease
Roivant and its spinout Priovant said this morning that their immune-modifying drug significantly outperformed placebo in clearing lesions caused by a rare skin disease in a small trial.Continue to STAT+ to read the full story…